showed a trendP = 0.044
On the other hand, mean pre-treatment HbA 1c was higher in mucinous (5.9% ± 0.4%) compared with non-mucinous (5.7% ± 0.3%, P = 0.007) adenocarcinomas and showed a trend to increasing concentrations from early (5.6%) to both advanced (5.8%, P = 0.044) and metastatic (5.8%, P = 0.020) CRC stages in non-diabetic patients (Anova test: F = 3.9, P = 0.021) (Figure 1 ).